capital · May 16, 2026
Allogene Therapeutics Reports Q1 2026 Results with Dagger Technology in ALLO-329 on May 13, 2026
Share the canonical public link.
Allogene Therapeutics reported first quarter 2026 financial results on May 13, 2026, including a net loss of $42.6 million and cash position of $266.9 million as of March 31, 2026. The company advanced ALLO-329, a dual-targeted CD19/CD70 AlloCAR T product incorporating proprietary Dagger technology for built-in targeted lymphodepletion by eliminating activated CD70-positive T cells. Nine patients have been treated in the Phase 1 RESOLUTION trial since November 2025 across dose levels of 20 million and 40 million cells. ALLO-329 showed signs of clinical activity and favorable tolerability with next update expected in Q4 2026. Allogene raised $200.4 million in gross proceeds from an April 2026 public offering extending cash runway into Q1 2029.